UPDATE
: Wednesday, December 11, 2019
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Celltrion targets Chinese biosimilar market through joint venture
by Lee Han-soo
2019-07-19 14:53
Biopharmaceutical stocks face grim outlook in 2H
by Jeong Sae-im
2019-07-17 14:11
Celltrion starts P1 trial of Xolair biosimilar
by Lee Han-soo
2019-07-15 17:45
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer
by Jeong Sae-im, Kim Yun-mi
2019-07-12 15:13
Court suspends decision on ministry’s order to revoke Invossa license
by Jeong Sae-im
2019-07-12 13:11
라인
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO
by Jeong Sae-im
2019-07-11 16:39
NKMax America seeks NASDAQ listing
by Jeong Sae-im
2019-07-11 12:41
Psomagen seeks KOSDAQ listing using technology exception policy
by Jeong Sae-im
2019-07-10 15:20
Kolon files administrative suit against Invossa license revocation
by Jeong Sae-im
2019-07-09 11:47
SillaJen shareholders panic over exec’s selling of 160,000 stocks
by Jeong Sae-im
2019-07-09 11:45
라인
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless
by Jeong Sae-im
2019-07-08 12:06
Victims question Kolon CEO’s sincerity in apology
by Jeong Sae-im
2019-07-05 15:14
Samsung, Genentech settle patent dispute on Herceptin biosimilar
by Lee Han-soo
2019-07-05 11:47
Kolon confident to resume US trial on Invossa
by Lee Hye-seon
2019-07-04 14:05
China OKs Alteogen’s Herceptin biosimilar for clinical trials
by Lee Han-soo
2019-07-04 14:04
라인
Regulator revokes Invossa license; Kolon CEO ‘to fight in court’
by Lee Hye-seon
2019-07-03 11:52
BNO BIO to invest $1 million in Israeli biotech venture
by Jeong Sae-im
2019-06-28 16:10
Shareholders in shock over HLB’s phase-3 trial setback
by Jeong Sae-im
2019-06-28 10:47
‘Food and drug ministry alone can’t handle Invossa debacle’
by Jeong Sae-im
2019-06-27 12:45
Oscotech wins exception policy for continued R&D for new drugs
by Jeong Sae-im
2019-06-25 14:11
-
1
2
3
4
5
6
7
8
9
10
다음
-
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
SNUH finds new direct method to treat endometrial injury
SK Bioscience's chickenpox vaccine world's 2nd to get WHO’s PQ certification
‘There should be no Invossa fiasco again’
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
SNUH finds new direct method to treat endometrial injury
SK Bioscience's chickenpox vaccine world's 2nd to get WHO’s PQ certification
‘There should be no Invossa fiasco again’
여백
Most viewed
1
Roche Diabetes Care stresses ‘integrated personalized diabetes management’
2
Gemvax & Kael unveils P2 trial result for Alzheimer treatment
3
Korea exports health insurance system to Bahrain
4
Syntekabio, CHA Hospital to co-develop immunotherapy
5
‘Endogenous T cells have high potential of treating blood, solid tumors’
6
AbbVie’s Venclexta nears insurance benefit
7
AMC unravels clues in treating relapsing, metastatic bladder cancer
8
‘Lynparza raises value of precision medicine as anticancer treatment’
9
Celltrion 1st Korean biopharmaceutical firm to achieve $1-billion exports
10
Korea selected as 'Medical Tourism Destination of the Year'
여백
Opinion
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
[Column] Korea should do better in diabetes management
[Column] Digital healthcare for efficient distribution of medical resources
여백
Back to Top